MXPA04000978A - Procedimiento para la produccion de 4-amino-2,5-bisheterociclilquinazolinas. - Google Patents

Procedimiento para la produccion de 4-amino-2,5-bisheterociclilquinazolinas.

Info

Publication number
MXPA04000978A
MXPA04000978A MXPA04000978A MXPA04000978A MXPA04000978A MX PA04000978 A MXPA04000978 A MX PA04000978A MX PA04000978 A MXPA04000978 A MX PA04000978A MX PA04000978 A MXPA04000978 A MX PA04000978A MX PA04000978 A MXPA04000978 A MX PA04000978A
Authority
MX
Mexico
Prior art keywords
ring
optionally substituted
heterocyclic ring
membered heterocyclic
compound
Prior art date
Application number
MXPA04000978A
Other languages
English (en)
Inventor
James Crook Robert
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA04000978A publication Critical patent/MXPA04000978A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invencion proporciona un procedimiento para la produccion de un compuesto de formula (A), o una sal o solvato farmaceuticamente aceptable del mismo, (ver formula). en la que R1 representa alcoxi CI-4 opcionalmente sustituido con uno o mas atomos de fluor; R2 representa H o alcoxi C1-6, opcionalmente sustituido con uno o mas atomos de fluor; R3 representa un anillo heterociclico de 5 o 6 miembros que esta opcionalmetne sustituido; R4 es un anillo heterociclico de 4, 5, 6 o 7 miembros que esta opcionalmente condensado con una anillo de benceno o un anillo heterociclico de 5 o 6 miembros, estando opcionalmente sustituido el sistema de anillo en conjunto; comprendiendo el procedimiento condensar un compuesto de formula (B) en la que R1 a R3 son como se han definido anteriormente; con un compuesto de formula (C), en la que R5 y R6, tomados conjuntamente con el atomo de N al que estan unidos, representan un anillo heterociclico que contiene N, de 4, 5, 6 o 7 miembros, estando opcionalmente condensado el anillo con un anillo de benceno o un anillo heterociclico de 5 o 6 miembros, estando opcionalmente sustituido el sistema de anillo en conjunto.
MXPA04000978A 2001-08-01 2002-07-19 Procedimiento para la produccion de 4-amino-2,5-bisheterociclilquinazolinas. MXPA04000978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0118752.5A GB0118752D0 (en) 2001-08-01 2001-08-01 Process for the production of quinazolines
PCT/IB2002/002872 WO2003011829A1 (en) 2001-08-01 2002-07-19 Process for the production of quinazolines

Publications (1)

Publication Number Publication Date
MXPA04000978A true MXPA04000978A (es) 2004-04-20

Family

ID=9919612

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000978A MXPA04000978A (es) 2001-08-01 2002-07-19 Procedimiento para la produccion de 4-amino-2,5-bisheterociclilquinazolinas.

Country Status (27)

Country Link
US (1) US7026479B2 (es)
EP (1) EP1412331B1 (es)
JP (1) JP2005501054A (es)
KR (1) KR20040019097A (es)
CN (1) CN1533378A (es)
AP (1) AP1299A (es)
AR (1) AR036204A1 (es)
AT (1) ATE323677T1 (es)
BR (1) BR0211670A (es)
CA (1) CA2451075A1 (es)
CZ (1) CZ2004151A3 (es)
DE (1) DE60210778T2 (es)
DO (1) DOP2002000443A (es)
EG (1) EG23204A (es)
ES (1) ES2260457T3 (es)
GB (1) GB0118752D0 (es)
HN (1) HN2002000197A (es)
HU (1) HUP0401573A3 (es)
IL (1) IL158998A0 (es)
MX (1) MXPA04000978A (es)
PA (1) PA8550301A1 (es)
PE (1) PE20030346A1 (es)
PL (1) PL368520A1 (es)
RU (1) RU2261861C1 (es)
UY (1) UY27399A1 (es)
WO (1) WO2003011829A1 (es)
ZA (1) ZA200309043B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
ATE532782T1 (de) * 2003-09-26 2011-11-15 Exelixis Inc C-met-modulatoren und anwendungsverfahren
CN1972688B (zh) * 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-苯胺基-喹唑啉-6-基-酰胺类化合物
US7985753B2 (en) * 2006-08-04 2011-07-26 Merz Pharma Gmbh & Co. Kgaa Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
EA019959B1 (ru) 2009-01-16 2014-07-30 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
IN2012DN00352A (es) * 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2888378C (en) * 2012-10-15 2015-09-22 Resverlogix Corp. Compounds useful in the synthesis of benzamide compounds
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719378D0 (en) * 1987-08-15 1987-09-23 Pfizer Ltd Antiarrythmic agents
EP0894797A4 (en) * 1997-01-09 2001-08-16 Terumo Corp NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS

Also Published As

Publication number Publication date
CZ2004151A3 (cs) 2005-01-12
HN2002000197A (es) 2003-02-27
ES2260457T3 (es) 2006-11-01
DOP2002000443A (es) 2003-02-15
UY27399A1 (es) 2003-02-28
AP2002002602A0 (en) 2002-09-30
HUP0401573A3 (en) 2005-06-28
RU2261861C1 (ru) 2005-10-10
DE60210778D1 (de) 2006-05-24
PL368520A1 (en) 2005-04-04
ZA200309043B (en) 2004-11-22
IL158998A0 (en) 2004-05-12
GB0118752D0 (en) 2001-09-26
ATE323677T1 (de) 2006-05-15
EG23204A (en) 2004-07-31
US7026479B2 (en) 2006-04-11
AP1299A (en) 2004-09-06
WO2003011829A1 (en) 2003-02-13
DE60210778T2 (de) 2007-01-04
CA2451075A1 (en) 2003-02-13
BR0211670A (pt) 2004-07-13
RU2004102692A (ru) 2005-07-10
KR20040019097A (ko) 2004-03-04
PE20030346A1 (es) 2003-04-05
EP1412331A1 (en) 2004-04-28
JP2005501054A (ja) 2005-01-13
EP1412331B1 (en) 2006-04-19
CN1533378A (zh) 2004-09-29
US20030100753A1 (en) 2003-05-29
PA8550301A1 (es) 2003-09-05
AR036204A1 (es) 2004-08-18
HUP0401573A2 (hu) 2005-01-28

Similar Documents

Publication Publication Date Title
AR023152A1 (es) Compuesto tienopirimidina, procedimiento para producirlo, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dichacomposicion
TW359670B (en) Process for producing quinazolin-4-one derivatives
HUP0401982A2 (hu) Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
ATE293101T1 (de) Piperidine zur verwendung als orexin rezeptor antagonisten
NZ532494A (en) Dibenzylamine compound and medicinal use thereof
TR200003332T2 (tr) İzoksazolin-3-il-asil benzen üretmek için yöntem
MY108967A (en) Triazolopyridazine compounds, their production and use
HUP0102723A2 (hu) Új difenilkarbamid-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
SE0101579D0 (sv) New compounds
MXPA04000978A (es) Procedimiento para la produccion de 4-amino-2,5-bisheterociclilquinazolinas.
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
HUP0500136A2 (hu) Oxitocin antagonista hatású szubsztituált diketo-piperazinok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
HUP0201356A2 (hu) Ösztrogén agonisták/antagonisták alkalmazása depresszió kezelésére vagy a kognitív funkció romlásának megelőzésére alkalmas gyógyászati készítmény előállítására
IE862630L (en) 3-VINYL AND 3-ETHYNYL-ß-CARBOLINES
NZ530043A (en) Hetero-bicyclic CRF antagonists
MXPA02012569A (es) Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
HUP0000321A2 (hu) NOS inhibitor hatású aromás aminszármazékok, eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények
MEP37508A (en) Process for the preparation of mesylates of piperazine derivatives
DE69430667T2 (de) Verfahren zur herstellung von fluoralkenylthio heterozyclische derivate
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
EA200400469A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
HUP0200808A2 (hu) Eljárás a piperazingyűrű kialakítására és új piperazinszármazékok
NO20031046D0 (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
ATE261441T1 (de) Analoga von distamycin-zimtsäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel

Legal Events

Date Code Title Description
FG Grant or registration